< Radiation Oncology < Bile duct
|
Front Page: Radiation Oncology | RTOG Trials |
|
|
Bile Duct: Main Page | Resectable Disease | Adjuvant RT | Unresectable Disease | Clinical Trials | | |
Link to Cancer.gov biliary tract cancer trials. Protocol ID below is cross-linked to the appropriate cancer.gov page.
Chemotherapy
| Phase | Protocol ID | Protocol Name |
|---|---|---|
| Phase III | XL119-001 | XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects with Advanced Biliary Tumors |
| Phase II | SWS-SAKK-44/02 | Phase II Study of Adjuvant Palliative Capecitabine and Gemcitabine in Patients With Locally Advanced or Metastatic Biliary Tract Cancer |
| Phase II | NYWCCC-0803945 | Phase II Study of 3-AP (Triapine®) and Gemcitabine in Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer |
| Phase II | FCCC-03042 | Phase II Study of Bortezomib as First-Line Systemic Therapy in Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder |
| Phase II | NCI-04-C-0273 | Phase II Study of Intrahepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion in Patients With Unresectable Primary or Metastatic Liver Cancer |
| Phase II | UTMB-NCI-931 | Phase II Randomized Study of Immunization With Carcinoembryonic Antigen (CEA) Peptide 1-6D Emulsified in Montanide ISA-51 Versus Dissolved in Sargramostim (GM-CSF) in HLA-A2+ Patients With CEA-Producing Adenocarcinomas of Gastrointestinal Tract Origin |
| Phase I/II | NCCTG-N9943 | Phase I/II Study of Gemcitabine and Pemetrexed Disodium in Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer |
This article is issued from Wikibooks. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.